Abstract
Background: Lactobacilli are the predominant bacteria in the vaginal tract, and while they are present, can prevent infectious situations, being used as probiotics for the health of the tract. Phytoderivatives are used historically to prevent or maintain the health of the tract, and is possible to combine both bioactives for novel vaginal formulas. The aim of this work was to study the effect of phytoderivatives (individual or combined extracts) on the growth of homologous vaginal lactic acid bacteria and their compatibility, to go further in the design of a combined pharmabiotic formula for the prevention or treatment of urogenital tract infections.Methods: the effect of phytocompounds approved by Pharcopoeias was evaluated on the growth of beneficial lactic acid bacteria previously isolated from the vaginal tract. Statistical methods, as CART, were applied to determine the stimulatory or inhibitory effect of the vegetal sources on bacterial growth by applying different methodology. Compatibility between phyto and lactobacilli was determined, and the phenolic compounds contents quantified, to define the optimal conditions for the formula design. Results: The BVL strains showing highest growth values with most of the phytoderivatives under study were L. gasseri CRL 1361, L. ga. CRL 1509 and L. ga. CRL 1263, and L. jensenii CRL 1333 and L. jen. CRL 1317, indicating the behavior is strain-dependent, and vegetable-compound-affected. The most adequate phytoderivatives were: Carica, Centella, Plantago, Uva ursi*, Zarzaparrila*, Cola de caballo, Echinaceae, Ortiga and Palo Azul.Conclusions: The BVL strains showing optimal resistance to the phytocompounds and compatibility with them were L. gasseri CRL 1320, 1307, 1509, L. salivarius CRL 1296 and L. rhamnosus CRL 1332 combined with Uva ursi*, Zarzaparrilla* and Echinaceae that will be used for the design of optimal phytobiotic formulas.
What kind of sanitation should be applied to remove Brettanomyces bruxellensis biofilms?
